JP2019536785A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536785A5
JP2019536785A5 JP2019528861A JP2019528861A JP2019536785A5 JP 2019536785 A5 JP2019536785 A5 JP 2019536785A5 JP 2019528861 A JP2019528861 A JP 2019528861A JP 2019528861 A JP2019528861 A JP 2019528861A JP 2019536785 A5 JP2019536785 A5 JP 2019536785A5
Authority
JP
Japan
Prior art keywords
methyl
pyrazole
fluorophenyl
alkyl
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019528861A
Other languages
English (en)
Japanese (ja)
Other versions
JP7373992B2 (ja
JP2019536785A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/063774 external-priority patent/WO2018102453A1/en
Publication of JP2019536785A publication Critical patent/JP2019536785A/ja
Publication of JP2019536785A5 publication Critical patent/JP2019536785A5/ja
Application granted granted Critical
Publication of JP7373992B2 publication Critical patent/JP7373992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019528861A 2016-11-30 2017-11-29 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法 Active JP7373992B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428271P 2016-11-30 2016-11-30
US62/428,271 2016-11-30
PCT/US2017/063774 WO2018102453A1 (en) 2016-11-30 2017-11-29 Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Publications (3)

Publication Number Publication Date
JP2019536785A JP2019536785A (ja) 2019-12-19
JP2019536785A5 true JP2019536785A5 (enExample) 2021-01-14
JP7373992B2 JP7373992B2 (ja) 2023-11-06

Family

ID=62241871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528861A Active JP7373992B2 (ja) 2016-11-30 2017-11-29 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法

Country Status (11)

Country Link
US (2) US11325903B2 (enExample)
EP (1) EP3548482A4 (enExample)
JP (1) JP7373992B2 (enExample)
CN (2) CN118930533A (enExample)
AU (1) AU2017366901B2 (enExample)
BR (1) BR112019011044A2 (enExample)
CA (1) CA3081983A1 (enExample)
IL (1) IL266930B2 (enExample)
MX (1) MX2019006299A (enExample)
NZ (1) NZ754827A (enExample)
WO (1) WO2018102453A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458445B1 (en) 2016-05-18 2021-02-17 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2017366901B2 (en) * 2016-11-30 2022-09-29 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
BR112019011035A2 (pt) * 2016-11-30 2019-10-15 Bantam Pharmaceutical Llc métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas
EP3710439B1 (en) 2017-11-15 2023-02-15 Mirati Therapeutics, Inc. Kras g12c inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019236966A2 (en) 2018-06-07 2019-12-12 Bantam Pharmaceutical, Llc Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849538A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
WO2020118066A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
CA3142196A1 (en) 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
EP3976605B1 (en) 2019-05-31 2025-08-20 Bantam Pharmaceutical, LLC Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor
JP7622043B2 (ja) 2019-08-29 2025-01-27 ミラティ セラピューティクス, インコーポレイテッド Kras g12d阻害剤
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
US20230212164A1 (en) * 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20230137286A (ko) 2020-09-11 2023-10-04 미라티 테라퓨틱스, 인크. Kras g12c 억제제의 결정 형태
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
US11999753B2 (en) 2020-12-16 2024-06-04 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
KR20240128852A (ko) 2021-12-01 2024-08-27 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체
JP2024543976A (ja) * 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化2-アミノ-3-シアノチオフェン及び誘導体
CN116678810A (zh) * 2022-02-23 2023-09-01 武汉市鼎华双雄生物科技有限责任公司 细胞增殖免疫荧光检测试剂盒及其应用
CN117003651B (zh) * 2023-09-28 2024-01-02 广东嘉博制药有限公司 一种l-肾上腺素的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301968B1 (it) 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
ES2208227T3 (es) 1999-12-03 2004-06-16 Pfizer Products Inc. Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos.
EP1513534A2 (en) 2002-04-04 2005-03-16 Cv Therapeutics, Inc. Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
US20060194807A1 (en) * 2003-04-03 2006-08-31 Cosford Nicholas D P Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
JP2006523701A (ja) 2003-04-18 2006-10-19 メルク エンド カムパニー インコーポレーテッド ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール
WO2007138110A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
MX2010001462A (es) 2007-08-27 2010-03-01 Basf Se Compuestos de pirazol para controlar plagas de invertebrados.
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
WO2014066304A1 (en) 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e
CA2943659C (en) * 2014-03-27 2023-04-25 Merck Patent Gmbh Pyridyl piperidines
WO2016169886A1 (en) 2015-04-24 2016-10-27 Syngenta Crop Protection Ag Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles
JP6707630B2 (ja) * 2015-06-01 2020-06-10 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーBantam Pharmaceutical, Llc 置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法
BR112019011035A2 (pt) * 2016-11-30 2019-10-15 Bantam Pharmaceutical Llc métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas
AU2017366901B2 (en) * 2016-11-30 2022-09-29 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
CA3142196A1 (en) * 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Similar Documents

Publication Publication Date Title
JP2019536785A5 (enExample)
JP2014506599A5 (enExample)
JP2018519323A5 (enExample)
JP6013375B2 (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
JP6647592B2 (ja) ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
JP6561167B2 (ja) 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物
ES2629414T3 (es) Derivados de tiazol
JP6964576B2 (ja) 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用
JPWO2020122093A5 (enExample)
JP2009524670A5 (enExample)
JP2016526576A5 (enExample)
JP2005538100A5 (enExample)
JP2012511588A5 (enExample)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2020516671A5 (enExample)
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
JP2012512886A5 (enExample)
HRP20030961A2 (en) Novel pyrrole derivatives as pharmaceutical agents
JP2010513444A5 (enExample)
JP2017530185A5 (enExample)
JP2012526774A (ja) アルドステロンシンターゼ阻害剤としてのアリールピリジン
JP2016513660A5 (enExample)
US20230382889A1 (en) Compounds for inhibiting kif18a
RU2016141647A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ